Soaring Medical Launches Non-Invasive High-Frequency Electrical Stimulation Device Targeting the Multi-Billion-Dollar Premature Ejaculation Market

Premature ejaculation is a common ejaculatory dysfunction. According to forecasts by贝哲斯咨询 (Beizhesi Consulting), the global market size for premature ejaculation treatment reached RMB 19.697 billion in 2022 and is projected to reach RMB 31.192 billion by 2028. During the forecast period, the compound annual growth rate (CAGR) of the global premature ejaculation treatment market is expected to be 7.96%.

This highly promising market has also led Aoxiang Medical to enter the fray.

Traditional delay products, such as delay sprays and medications, were once popular but have often become a source of frustration for users due to side effects, inconvenience in use, and inconsistent efficacy. Achieving success by replicating past approaches has become increasingly challenging. Based on market insights,Aoxiang Medical has chosen a relatively unique path by offering treatment solutions for premature ejaculation based on “non-invasive high-frequency electrical stimulation nerve block technology.”

Fundamentally distinct from conventional low-frequency (<1 kHz) electrical stimulation, which is typically employed to elicit action potentials by exciting neuronal structures, Aoxiang Medical’s proprietary non-invasive high-frequency electrical stimulation technology (>1 kHz) generally induces sustained depolarization of nerve axons or inactivation of sodium channels. This reversibly inhibits the propagation of action potentials in the stimulated region, thereby achieving a nerve block effect.

As early as 2019, the Aoxiang Medical team began closely monitoring and tracking this cutting-edge technology. The head of Aoxiang Medical told VCBeat that the team initially focused primarily on the field of pain management.

In 2010, Nevro’s 10 kHz Nevro^® Senza^® The SCS system has received CE certification for pain management. Meanwhile, Neuros Medical and ENSO have respectively launched implantable peripheral nerve stimulation devices based on high-frequency electrical stimulation and non-invasive high-frequency electrical stimulation products for pain relief.

As research into non-invasive high-frequency electrical stimulation for nerve block advances, the Aoxiang Medical team has gradually come to realize that its application potential extends far beyond pain management. “The efficacy of this technique in pain treatment stems from its ability to inhibit sensory nerves that transmit pain signals. This finding has also prompted us to explore its potential in treating premature ejaculation,” emphasized the head of Aoxiang Medical.“Traditionally, the treatment of premature ejaculation has largely relied on dorsal neurectomy; however, this approach is highly invasive and irreversible, resulting in generally low patient acceptance.””

To validate the feasibility of electrical stimulation technology in the treatment of premature ejaculation, Aoxiang Medical collaborated with Professor Deng Chunhua, former Chairman of the Andrology Branch of the Chinese Medical Association and Director of the Department of Andrology at the First Affiliated Hospital of Sun Yat-sen University. Through more than two years of joint efforts, Aoxiang Medical innovated and optimized electrical stimulation parameter protocols based on non-invasive high-frequency electrical stimulation technology, focusing on the characteristics of the dorsal penile nerve. It is reported thatThe core of non-invasive high-frequency electrical stimulation technology lies in the use of frequencies at or above 10 kHz (while also encompassing multiple other key parameter combinations) to inhibit sodium channel depolarization, thereby preventing the generation of action potentials. This effectively reduces the transmission of abnormal signals and decreases the excitability of neural networks.

In clinical observations conducted by Aoxiang Medical Organization, 20 volunteers with severe premature ejaculation were involved. All participants had failed to respond to existing treatments for premature ejaculation and exhibited an intravaginal ejaculatory latency time (IELT) of less than one minute. The volunteers self-administered electrostimulation training using Dianjile at home two to three times daily, with each session lasting one minute. Efficacy assessments began after one to two weeks of continuous treatment. The results showed thatThe treatment efficacy rate is as high as 90%, with approximately 50% of patients experiencing an extended intravaginal ejaculatory latency time (IELT) to 3–5 minutes, and 30% achieving an extension to 6–10 minutes.

Currently, Aoxiang Medical has officially launched its first product, Dianjile.The core highlight of this product lies in its adoption of non-invasive high-frequency electrical stimulation technology, eliminating reliance on traditional chemical drugs and irritating ingredients, thereby providing a new solution for the treatment of men's health issues.

According to the head of Aoxiang Medical, Dianjile was originally designed to help male patients enhance ejaculatory control through physical training. With long-term use, users need only perform one minute of physical training per week to achieve significant therapeutic effects. This convenient and highly effective treatment approach offers a welcome solution for men seeking delayed ejaculation options, while also avoiding potential health risks associated with medication.

“Dianjile” product image, provided by the interviewee

In terms of design, Dianjile also demonstrates its innovative aspects.. The product features a compact, portable design similar in size to a lighter, with simple and intuitive operation, enabling male users to complete the treatment process at home while fully safeguarding their privacy.This design not only makes treatment more convenient but also reduces the psychological burden on users, so that the need for delaying ejaculation is no longer a burden.

In January 2025, Aoxiang Medical commenced mass production of Dianjile and began assembling a professional sales team. In addition to establishing offline coverage in key andrology hospitals within the traditional medical market, Aoxiang Medical will actively expand online sales channels for various andrology products, working with partners to advance collaborative efforts.

Furthermore, Aoxiang Medical plans to prioritize collaborations with ten andrology centers in China for clinical research. Meanwhile, the company is actively engaging with andrology experts in Europe and the United States to explore opportunities for clinical studies, with the aim of strategically expanding into European and American markets in the future.

It is worth noting that the application potential of non-invasive high-frequency electrical stimulation technology extends far beyond the field of andrology.

According to the head of Aoxiang Medical, non-invasive high-frequency electrical stimulation technology is effective for a series of diseases caused by peripheral nerve hyperexcitability or abnormal conduction,Such as various pain management, ear, nose and throat diseases, hyperhidrosis, premature ejaculation, and urinary incontinence, all demonstrate significant therapeutic potential.. Currently, these four products based on non-invasive high-frequency electrical stimulation technology are at different stages of research and development.

In its premature ejaculation treatment product line, Aoxiang Medical is actively advancing the development of its second-generation products.This upgrade not only focuses on the deep integration of in-hospital usage scenarios but also fully considers users’ diverse treatment needs, including varying preferences for short-term and long-term regimens.Based on these considerations, Aoxiang Medical plans to precisely position and iteratively upgrade its second-generation products, providing users with more personalized and efficient treatment solutions.